FDA approval makes Differin Epiduo Acne Gel available OTC for patients aged 12 years or older with acne.
The US Food and Drug Administration (FDA) has approved Differin Epiduo Acne Gel, a fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5%, for over-the-counter (OTC) use in patients aged 12 years or older, according to an announcement from Galderma.1 The prescription-to-OTC switch makes the topical retinoid–benzoyl peroxide combination available without a prescription in the US, while Epiduo remains prescription-only outside the US.
The approval is intended to bring “proven acne science to a broader population of acne sufferers through wider access” to the combination product, according to Galderma.1 For clinicians, the decision may affect counseling for adolescents and adults with mild to moderate acne who self-treat before seeking dermatology or primary care evaluation.
Differin Epiduo combines adapalene, a third-generation topical retinoid, with benzoyl peroxide in a once-daily gel formulation. Adapalene targets abnormal follicular keratinization and has anti-inflammatory activity, whereas benzoyl peroxide provides antimicrobial activity against Cutibacterium acnes and has mild comedolytic effects. Current acne guidelines support topical retinoids, benzoyl peroxide, and fixed-dose topical combinations as foundational therapies for many patients with acne vulgaris, with selection guided by acne severity, lesion type, tolerability, pregnancy considerations, and patient preference.2
Key Facts
The FDA action was based on prior clinical and real-world use data for the adapalene/benzoyl peroxide combination, according to Galderma.1 The company cited multiple randomized, controlled phase 3 studies in which adapalene/benzoyl peroxide gel outperformed adapalene alone, benzoyl peroxide alone, and vehicle across inflammatory, noninflammatory, and total lesion counts, as well as Investigator Global Assessment success, defined as clear or almost clear.1 In one 12-week randomized trial, the fixed-dose combination demonstrated greater reductions in acne lesions than its individual components or vehicle and had an early onset of effect, with Galderma reporting clinically meaningful lesion count improvement as early as week 1.1,3
A separate pivotal trial published in the Journal of the American Academy of Dermatology similarly evaluated the fixed-dose adapalene 0.1%/benzoyl peroxide 2.5% gel in acne vulgaris and found the combination provided greater efficacy than monotherapy components or vehicle.4 Galderma also cited long-term single-arm data showing sustained efficacy through 12 months, with approximately 65% total lesion reduction maintained over that period.^1^ The company reported favorable tolerability across skin tones but did not provide new safety data in the announcement.
Acne remains one of the most common dermatologic conditions encountered in clinical practice, particularly among adolescents and young adults, and can be associated with dyspigmentation, scarring, and psychosocial burden.2 OTC options have historically included benzoyl peroxide, salicylic acid, sulfur-based products, and, since a prior prescription-to-OTC switch, adapalene 0.1% gel. The new approval expands OTC access to a fixed-dose retinoid–benzoyl peroxide combination rather than a single active ingredient.
The clinical relevance of the switch will likely depend on patient selection and counseling. Fixed-dose combinations can simplify regimens and may improve adherence, but retinoids and benzoyl peroxide can cause dryness, erythema, peeling, burning, and irritation, particularly early in treatment. Patients also may overuse topical products, combine multiple irritants, or discontinue therapy before the expected response window. Clinicians may need to reinforce gradual initiation, moisturizer use, photoprotection, and avoidance of unnecessary duplicate acne actives.
The OTC label applies to patients aged 12 years or older in the US.1 The announcement did not include the FDA’s detailed review documents, postmarketing commitments, or a newly published switch study, so interpretation is limited to the company-reported regulatory update and previously published acne trials. Unanswered questions include how nonprescription availability will influence appropriate use, treatment persistence, adverse-event reporting, and timely referral for patients with nodulocystic acne, scarring, hyperpigmentation, or inadequate response to topical therapy.
Galderma stated Differin Epiduo is expected to be available at major US retailers beginning in summer 2026.1
References
